Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
biosimilars
Pharma
Coherus sells Neulasta biosimilar to Intas for up to $558M
Coherus has scored up to $558 million for the last biosimilar in its portfolio, freeing up the company to go all.in on Loqtorzi.
Fraiser Kansteiner
Dec 3, 2024 4:16pm
EU regulators endorse meds from BMS, J&J, Eisai and more
Nov 15, 2024 10:05am
Hefty sales of generics boost Teva to another big quarter
Nov 6, 2024 3:19pm
Amgen reaps Horizon buyout rewards in Q3, preps biosim launches
Oct 31, 2024 7:50am
Roche's Vabysmo will rise above Eylea biosim threat, exec says
Oct 23, 2024 11:24am
Amgen gears up to launch Eylea biosim as Regeneron plots appeal
Oct 23, 2024 10:16am
